viewe-Therapeutics PLC

e-Therapeutics and C4x Discovery team up to find new Parkinson’s treatments

By combining both of their technologies, the companies think they can identify better treatments for Parkinson’s disease

elderly man
The combination could also help find new treatments for disorders such as Alzheimer’s and MS

e-Therapeutics PLC (LON:ETX) has teamed up with C4X Discovery Holdings plc (LON:C4XD) in a bid to find new treatments for Parkinson’s disease.

Parkinson’s is a long-term degenerative disorder, with typical symptoms including shaking and slowness of movement.

There is currently no cure for the disease, with treatments aimed instead at improving symptoms, albeit with limited success.

READ: ETX sees biopharma sector get in tune with its way of thinking

C4X’s Taxonomy-3 platform uses sophisticated algorithms that run over genetic data time and again to identify the genes that contribute to someone having a disease.

So far, the technology has thrown up around 200 genes associated with Parkinson’s, which ETX has further analysed using its Network-Driven Drug Discovery (NDD) approach.

“By using the advanced computational analytics of our NDD platform, we have been able to confirm the centrality of a number of known mechanisms in PD and, importantly, identify potential new ones,” said ETX’s head of discovery biology, Alan Whitmore.

“This in turn, opens up the prospect of new approaches to the discovery of effective novel drugs to tackle this and other undertreated, debilitating conditions.”

C4X’s chief scientific officer Craig Fox added: “This combination [with ETX] has identified additional novel biological pathways for the treatment of PD and we look forward to moving these findings forward to initiate new drug discovery programmes.”

While both companies believe this approach could help to identify better treatments for PD, they think it could also work for other degenerative disorders such as Alzheimer’s and multiple sclerosis.

Quick facts: e-Therapeutics PLC

Price: 14.25 GBX

Market: AIM
Market Cap: £59.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...


2 min read